ArticleFrontiers in oncology2026
Novel Bragg peak FLASH radiotherapy: treatment of base-of-skull tumors within existing clinical guidelines.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Proton therapy is commonly delivered for base-of-skull (BOS) tumors to minimize risk of normal-tissue injury. Novel Bragg peak FLASH may improve protection for organs at risk (OARs). We investigated if proton pencil-beam scanning (PBS) Bragg peak FLASH could achieve comparable dosimetry at ultra-high dose rates to conventional-rate (CONV)-intensity-modulated proton therapy (IMPT) for potential clinical use. Materials and methods: PBS Bragg peak FLASH and CONV-IMPT plans were optimized for 10 consecutive patients with BOS tumor in an in-house treatment-planning system and hypofractionation regimen (30 GyE in five fractions) to assess dosimetric quality while reflecting clinical practice, parameters, and hypothetical fraction doses for FLASH effect. FLASH dose-rate coverage ( Results: FLASH generated higher CTV Conclusion: PBS Bragg peak FLASH can deliver conformal target dosimetric coverage, ultra-high dose rates, and comparable OAR dosimetry to CONV-IMPT, suggesting that this novel technique is feasible for BOS tumor FLASH radiotherapy. The study supports future research to explore FLASH's biological and clinical benefits in BOS tumors and OAR sparing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.